We mobilized peripheral blood stem cells (PBSC) following CHOP plus rituximab (CHOP-R) therapy, and compared with the findings following CHOP therapy without rituximab. All patients were given G-CSF starting from day 11 after CHOP therapy. Patients in the CHOP-R group (n ¼ 8) were given rituximab on day 12. Target CD34 þ cells number was collected in a single leukapheresis on day 14, from all the eight patients in the CHOP-R group. PBSC mobilization kinetics, CD34
Summary:
We mobilized peripheral blood stem cells (PBSC) following CHOP plus rituximab (CHOP-R) therapy, and compared with the findings following CHOP therapy without rituximab. All patients were given G-CSF starting from day 11 after CHOP therapy. Patients in the CHOP-R group (n ¼ 8) were given rituximab on day 12. Target CD34 þ cells number was collected in a single leukapheresis on day 14, from all the eight patients in the CHOP-R group. PBSC mobilization kinetics, CD34
þ cells yield and colony-forming ability in the graft collection, toxicity during mobilization, and engraftment after transplantation of CHOP-R group were not significantly different from those in the CHOP group (n ¼ 8). In all patients given CHOP-R therapy, CD20
þ cells and immunoglobulin heavy chain (IgH) rearrangement in the graft collection were undetectable by flow-cytometric analysis and Southern blot analysis, respectively, but with PCR analysis two of eight grafts were positive for IgH rearrangement. While further studies are needed to evaluate the efficacy of purging and the outcome of patients undergoing autologous transplantation, CHOP-R therapy can be safely and effectively used in the mobilization phase of PBSC collection, without excess clinical toxicity or deleterious effect on PBSC mobilization kinetics or engraftment time. High-dose chemotherapy followed by autologous peripheral blood stem cell transplantation (APBSCT) has been widely used for patients with non-Hodgkin's lymphoma (NHL).
1,2 One major obstacle to APBSCT is peripheral blood (PB) cell involvement with lymphoma cells. Several studies have shown that the reduction of tumor burden in vivo and purging of autografts reduce the risk of contamination by lymphoma cells of the graft, and may improve outocome. 3, 4 Some strategies to eliminate contaminating lymphoma cells in the graft are being tested, including in vitro purging of grafts with monoclonal antibodies and complement, 5 CD34 þ cell selection, 6 and in vivo purging of PB.
Rituximab, a highly specific mouse/human chimeric anti-CD20 antibody (Chugai Pharmaceutical Co. Ltd, Tokyo, Japan), has been seen to cause a rapid depletion of PB B-cells. 7 Regimens, such as high-dose cytosine arabinoside, 8, 9 HAM (high-dose cytosine arabinoside/ mitoxantrone), 10 and DexaBEAM (dexamethasone/ BCNU/etoposide/cytosine arabinoside/melphalan), 11 have been used in conjunction with rituximab during mobilization procedures, to obtain tumor-free progenitor cells. Although sufficient numbers of PBSC could be obtained using these regimens, the timing of leukapheresis differed with each case, because decisions were based on measurement of CD34 þ cells or platelet recovery in the PB. For patients with NHL, CHOP therapy remains the best available combination chemotherapy. 12 We found no published information addressing the kinetics of PBSC and graft acquisition following therapy with CHOP and rituximab, and we wish to report our experience here. The optimum timing of leukapheresis and effects of rituximab on PBSC mobilization, purging, engraftment, and toxicity are discussed. , when rituximab became available in Japan, PBSC were mobilized using CHOP plus rituximab regimen combined with G-CSF (CHOP-R group, n ¼ 8). Thus CHOP and CHOP-R groups were sequentially recruited. Characteristics of these two groups are listed in Table 1 .
Patients and methods

Patients
Premobilization phase
All patients were given three cycles of biweekly CHOP therapy with G-CSF support as induction chemotherapy prior to mobilization ( orally from day 1 to day 5. Patients were given G-CSF (Lenograstim, Chugai Pharmaceutical Co., Tokyo, Japan) at a dose from 1 to 5 mg/kg/day, subcutaneously, starting from the day when the total leukocyte count was o3.0 Â 10 9 /l. Thereafter, it was withdrawn when the leukocyte count exceeded 10 Â 10 9 /l, and the next cycle of CHOP therapy was immediately started.
14 No patients, including the patients in the CHOP-R group, were given rituximab in the premobilization phase.
Mobilization and collection of PBSC
One or two leukaphereses were performed after the fourth cycle of biweekly CHOP therapy. CY dose was increased to 1000 mg/m 2 . Mobilization and collection of PBSC were scheduled as follows: The first day of leukapheresis after the start of CHOP therapy was fixed on day 14. Until day 10, patients were given G-CSF (lenograstim) in a dose of 1 mg/kg/day, subcutaneously, when the total leukocyte count was o3.0 Â 10 9 /l. All patients were given G-CSF in a dose of 5-10 mg/kg/day, subcutaneously, starting from day 11 until the day of the last apheresis. 15 All the eight patients in the CHOP-R group were given rituximab 375 mg/m 2 2 days before stem cell collection (day 12 of the CHOP regimen). PBSC collections were made on day 14, using either Cobe Spectra (Lakewood, CO, USA) or CS3000 (Baxter-Fenwal Division, Deerfield, IL, USA). A minimum threshold requirement of CD34 þ cells was 1.5 Â 10 6 cells/kg.
In vitro assays
PB samples for mobilization kinetics analysis of CD34 þ cells were obtained from day 12 to the end of PBSC apheresis. Flow-cytometric (FCM) analysis of CD34 þ cells and colony-forming units-granulocyte/macrophage (CFU-GM) and burst-forming unit-erythrocyte (BFU-E) colony assay allowed for estimation of the number of progenitor cells in the collection. Colony assay was done using serum containing fibrin clots, 16 with 2 U/ml of recombinant human erythropoietin, 50 U/ml of recombinant interleukin 3, 50 ng/ml of recombinant GM-CSF, and 50 ng/ml of recombinant G-CSF, in flat-bottomed, 24-well-tissue culture plates in a 5% CO 2 /95% atmosphere incubator at 371C for 14 days. The clots were stained with benzidinehematoxylin, and for identification the colonies were enumerated using the criteria of Clarke and Housman. 17 
Toxicity during PBSC mobilization
All adverse reactions were recorded and graded according to National Cancer Institute criteria.
Transplantation procedure
Pre-transplant conditioning regimens for all patients consisted of ranimustine (MCNU) 200 mg/m 2 once daily i.v., on days À8 and À3 (total dose 400 mg/m 2 ), carboplatin (CBDCA) 300 mg/m 2 once daily i.v. on days À7 to À4 (total dose 1200 mg/m 2 ), etoposide (VP-16) 500 mg/m 2 once daily i.v. on days À6 to À4 (total dose 1500 mg/m 2 ), and CY 50 mg/kg once daily i.v. on days À3 and À2 (total dose 100 mg/kg) (MCVC regimen). 18 All patients were given G-CSF (5 mg/kg/day subcutaneously) from day þ 1 until engraftment. All patients in the CHOP-R group were given rituximab 375 mg/m 2 weekly for 3 weeks after engraftment.
Evaluation of purging
In the CHOP-R group, the numbers of CD20 þ cells in PB were compared before and after rituximab administration, that is, day 12 and day 14 of the fourth cycle of CHOP therapy, respectively. Minimal residual disease (MRD) in the graft collection was evaluated using FCM analysis of CD20 þ cells, Southern blot analysis, and polymerase chain reaction (PCR) analysis of immunoglobulin heavy chain (IgH) rearrangement. Primers for the PCR assay were made for each patient, according to their lymphoma-cell specific base sequence of the third complementaritydetermining region (CDR-III) of IgH. PCR assays were carried out at Mitsubishi Kagaku Bio-Clinical Laboratories, Tokyo, Japan.
Statistical methods
Statistical comparisons were made between the CHOP and CHOP-R groups. The Mann-Whitney U-test was used for comparisons regarding CD34 þ cell mobilization, CFU-GM, and BFU-E in PB samples or apheresis products. Comparisons of the number of CD20 þ cells in PB before and after rituximab administration were made using the Wilcoxon signed-ranks test. P-values o0.05 were considered significant.
Results
Mobilization of circulating CD34
þ cells (Table 2) Mobilization kinetics of PB CD34 þ cells in the CHOP and CHOP-R groups are shown in Table 2 . The median PB CD34 þ cell count on day 14 of CHOP therapy was 27.0 Â 10 6 /l, and 39.1 Â 10 6 /l in the CHOP and CHOP-R groups, respectively. These numbers of mobilized PB CD34 þ cells were sufficient for leukapheresis. Rituximab does not seem to adversely affect mobilization kinetics.
PBSC collection (Table 3) PBSC collection data are summarized in Table 3 . The total doses of G-CSF given for mobilization were not significantly different between groups. The target CD34 þ cell number was collected from all eight patients in the CHOP-R group in a single leukapheresis. For three of eight patients in the CHOP group, two leukaphereses were required. The median CD34 þ cells yield in the graft collection was 2.29 Â 10 6 /kg in patients on CHOP-R compared with 2.90 Â 10 6 /kg for the CHOP group. Colony assays of CFU-GM and BFU-E from stem cell grafts in the CHOP-R group are not significantly different from those assayed in the CHOP group.
Engraftment (Table 4)
Engraftment data are summarized in Table 4 . Eight patients in the CHOP-R group achieved neutrophil engraftment at a median of 10 (range 9-11) days and platelet transfusion independence at a median of 15.5 (range 10-30) days. There was no significant difference in time to neutrophil engraftment or platelet independence and transfusion requirements among patients mobilized with or without rituximab.
Toxicity
There was no significant toxicity during mobilization with CHOP-R. Five patients experienced grade 1 fever. One patient experienced mild tightness sensation in the throat and another patient experienced eyelid edema, which resolved on decreasing the infusion rate of rituximab. Table 4 Engraftment times and transfusion requirement
No. of days to neutrophil engraftment (neutrophil count 40.5 Â 10 Purging efficiency with rituximab CD20 þ cells in the PB after rituximab (day 14 after CHOP) decreased significantly (P ¼ 0.018) compared with findings before the use of rituximab (day 12 after CHOP). In all patients on CHOP-R, CD20
þ cells and IgH rearrangement were undetectable in the graft collection by FCM and Southern blot analysis, respectively. For eight patients receiving CHOP-R, two were positive for IgH rearrangement on PCR analysis of the graft collection.
Discussion
Rituximab caused a rapid depletion of PB B-cells. 7 Recent studies show that rituximab has the potential, in conjunction with chemotherapy, to allow harvesting of tumor-free progenitor cells for patients with B-cell NHL. [8] [9] [10] However, reports of its effects on stem cell mobilization kinetics and engraftment are few. 19 Our study shows that stem cell mobilization with CHOP-R therapy is safe and does not adversely affect the number or function of stem cells, compared with mobilization with CHOP therapy without rituximab.
It is important to know the stem cell mobilization kinetics in the course of a mobilization regimen to set up the day of leukapheresis in advance. In almost all reported mobilization regimens, the day of leukapheresis was determined by monitoring PB CD34 þ cells number, neutrophils or platelet recovery in PB; so it differed with each case. [8] [9] [10] Buckstein et al 19 reported the stem cell mobilization kinetics after 5 consecutive days of administration of G-CSF, and they started leukapheresis from day 5. They collected sufficient number of stem cells, but some patients needed two or three leukaphereses to meet the target number of stem cells. In our study, a single leukapheresis (day 14 after CHOP) was sufficient to meet the target number of stem cells in all eight patients mobilized while on the CHOP-R regimen. This makes scheduled leukapheresis possible; one can decide the day of leukapheresis before starting the mobilization regimen. Furthermore, CHOP with rituximab has become one of the standard regimens for patients with B-cell NHL; so mobilization with CHOP-R will make leukapheresis feasible during lymphoma therapy, without any additional regimen for mobilization.
Our data show that CD20 þ cells and IgH rearrangement in PBSC collections were undetectable by FCM and Southern blot analysis, respectively, in all eight patients receiving CHOP-R therapy. However, two of eight PBSC collections were not free of lymphoma contamination determined by PCR. It is not clear whether these positive grafts contained viable or nonviable lymphoma cells undergoing apoptosis, because rituximab was administered only 2 days before the stem cell collection. In fact, IgH rearrangement of bone marrow and PB mononuclear cells became undetectable by PCR after transplantation in all patients on CHOP-R therapy, including those reinfused with a PCR-positive graft. Further studies are needed to clarify the optimum timing and ideal number of rituximab administrations before PBSC mobilization.
CD34
þ cell-positive selection can also eliminate tumor cells from graft collections. 6 However, loss of stem cells during selection procedures and a higher rate of infectious complications after transplantation are major problems with the method. 20 With in vivo purging with rituximab, stem cell loss cannot occur. It is not clear whether infectious complications increase or not after transplantation using a graft mobilized with rituximab.
Our study population was small and there are some differences in patient demographics. In particular, 3/4 of the CHOP-R group had bone marrow involvement by lymphoma cells compared to 1/8 in the CHOP group. The presence of bone marrow involvement is disadvantageous for mobilizing PBSC. However, sufficient PBSC were collected from all eight patients in the CHOP-R group, and they did not differ significantly from those collected in the CHOP group. Therefore, at least, rituximab does not seem to adversely affect PBSC mobilization.
In conclusion, CHOP-R therapy can be safely and effectively used in the mobilization phase of PBSC collection without excessive clinical toxicity or deleterious effects on PBSC mobilization kinetics or engraftment times, and hence scheduled leukapheresis is feasible. The efficacy of purging on eliminating contaminating lymphoma cells in the graft with CHOP-R therapy and improving the outcome of patients undergoing autologous transplantation are subjects of ongoing study.
